01Feb 2023
Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate

Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate

Starting January 1, 2021, Centers for Medicare and Medicaid Services required United States hospitals to publicly disclose the prices of their services provided. The study analyzed publicly-disclosed prices of prostate cancer-related services. Based on the study results, it was concluded that self-pay prices of prostate cancer services were generally higher than insurance-negotiated prices and were higher at for-profit hospitals, academic hospitals, and hospitals in the highest quartile of gross annual revenue. Higher neighbourhood hospital density was not associated with higher likelihood of price disclosure nor lower pricing of services, suggesting that local competition does not lead to lower prices and may disincentivize disclosure of prices.

  • #urology

Like

Save

Share